US Patent Issued to ANAVEX LIFE SCIENCES on Aug. 12 for "Optimized sigma-1 agonist method of responder selection and treatment" (French, American Inventors)

ALEXANDRIA, Va., Aug. 12 -- United States Patent no. 12,383,526, issued on Aug. 12, was assigned to ANAVEX LIFE SCIENCES CORP. (New York).

"Optimized sigma-1 agonist method of responder selection and treatment" was invented by Christopher U. Missling (New York), Mohammad Michel Afshar (Paris) and Frederic Parmentier (Fresnes, France).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present disclosure provides genetic polymorphisms associated with an altered response of a subject to Sigma-1 receptor therapy. Also described is use of the polymorphisms to personalize treatment for subjects in need of Sigma-1 receptor therapy such as treatment of neurodevelopmental and neurodegenerative diseases and conditions....